文献速递神经儿科影像MR

儿童高级别中线丘脑胶质瘤的MRI与分子特征:HERBY II期试验

MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
PubMed 文献 · Radiology · 2022-04-12

本研究为HERBY前瞻性试验的二次分析,纳入42例可影像评估的丘脑弥漫性中线胶质瘤患儿,依据MRI确定肿瘤中心位置及范围并关联分子分型与生存。结果显示丘脑受累范围从部分丘脑到全丘脑或双丘脑弥漫连续扩散不等,结局均差且与H3 K27突变亚型无关;术前已发生软脑膜转移及手术切除不足50%为不良预后因素。

要点

  • 丘脑弥漫性中线胶质瘤可表现为部分丘脑、全丘脑、单丘脑弥漫连续延伸或双丘脑受累,总体结局差。
  • 术前已出现软脑膜转移者预后更差:无事件生存2.9个月 vs 8.0个月(P = .02),总生存11.4个月 vs 18.5个月(P = .004)。
  • 行大部减瘤或全切除/近全切除者总生存更长:18.5个月 vs 11.4个月(P = .02)。

核心结论

  • 丘脑弥漫性中线胶质瘤的丘脑受累范围从局限性部分丘脑到全丘脑或双丘脑弥漫连续扩散不等,结局均差且与H3 K27亚型改变无关;软脑膜播散和手术切除不足50%为生存的不良危险因素。

研究设计与样本

  • HERBY前瞻性试验(NCT01390948,2011年10月至2016年2月)的二次分析,121例参与者中50例为中线非脑桥肿瘤,其中42例(平均年龄12岁±4,23例女孩)为可影像评估的丘脑弥漫性中线胶质瘤。

关键影像表现/征象

  • 18例为部分丘脑受累(12例丘脑枕,6例前内侧),10例累及整个丘脑,9例为单丘脑肿瘤伴弥漫连续延伸,5例为双丘脑肿瘤(2例对称,3例部分)。
  • 丘脑弥漫性中线胶质瘤的丘脑受累范围可从局限性部分丘脑延伸至全丘脑或双丘脑弥漫连续扩散。

诊断标准与关键数值

  • 丘脑弥漫性中线胶质瘤被重新分类为H3 K27突变型、H3野生型伴zest同源物抑制蛋白过表达、表皮生长因子受体突变型或未另行说明。
  • 28例为H3 K27突变型肿瘤,与其他弥漫性中线胶质瘤(n = 4)相比结局无差异。

临床应用与阅片要点

  • 阅片时应评估丘脑受累范围(部分、全部、单侧弥漫连续延伸或双侧)及是否存在软脑膜转移。
  • 术前已出现软脑膜转移提示无事件生存和总生存更差。
  • 手术切除范围不足50%与总生存较短相关,大部减瘤或全切除/近全切除者总生存更长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Diffuse midline gliomas (DMG) are characterized by a high incidence of H3 K27 mutations and poorer outcome. The HERBY trial has provided one of the largest cohorts of pediatric DMGs with available radiologic, histologic-genotypic, and survival data. Purpose To define MRI and molecular characteristics of DMG. Materials and Methods This study is a secondary analysis of a prospective trial (HERBY; ClinicalTrials.gov identifier, NCT01390948) undertaken between October 2011 and February 2016. Among 121 HERBY participants, 50 had midline nonpontine-based tumors. Midline high-grade gliomas were reclassified into DMG H3 K27 mutant, H3 wild type with enhancer of zest homologs inhibitory protein overexpression, epidermal growth factor receptormutant, or not otherwise stated. The epicenter of each tumor and other radiologic characteristics were ascertained from MRI and correlated with the new subtype classification, histopathologic characteristics, surgical extent, and outcome parameters. Kaplan-Meier curves and log-rank tests were applied to determine and describe survival differences between groups. Results There were 42 participants (mean age, 12 years ± 4 [SD]; 23 girls) with radiologically evaluable thalamic-based DMG. Eighteen had partial thalamic involvement (12 thalamopulvinar, six anteromedial), 10 involved a whole thalamus, nine had unithalamic tumors with diffuse contiguous extension, and five had bithalamic tumors (two symmetric, three partial). Twenty-eight participants had DMG H3 K27 mutant tumors; there were no differences in outcome compared with other DMGs (n = 4). Participants who underwent major debulking or total or near-total resection had longer overall survival (OS): 18.5 months vs 11.4 months (P = .02). Enrolled participants who developed leptomeningeal metastatic dissemination before starting treatment had worse outcomes (event-free survival, 2.9 months vs 8.0 months [P = .02]; OS, 11.4 months vs 18.5 months [P = .004]). Conclusion Thalamic involvement of diffuse midline gliomas ranged from localized partial thalamic to holo- or bithalamic with diffuse contiguous spread and had poor outcomes, irrespective of H3 K27 subtype alterations. Leptomeningeal dissemination and less than 50% surgical resection were adverse risk factors for survival. Clinical trial registration no. NCT01390948 © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Widjaja in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Rodriguez, Calmon, Aliaga, et al. MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology. 2022. PMID: 35412366. doi:10.1148/radiol.211464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。